Provided by Tiger Trade Technology Pte. Ltd.

Incyte

123.28
-2.7300-2.17%
Post-market: 124.481.20+0.97%18:42 EDT
Volume:1.46M
Turnover:181.20M
Market Cap:24.99B
PE:15.70
High:126.31
Open:125.09
Low:122.58
Close:126.01
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.07
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.94
PE(LYR):19.23

Loading ...

Top Incyte Executives Quietly Lock In Profits With Fresh Stock Sales

TIPRANKS
·
Jul 21

Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Incyte EVP, Head of U.S. Commercial Issa Mohamed Khairie Sells 1,093 Shares for $125,705.93

Reuters
·
Jul 21

Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug

MT Newswires Live
·
Jul 20

Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating

MT Newswires Live
·
Jul 20

Halozyme announces global collaboration, license agreement with Incyte

TIPRANKS
·
Jul 20

Halozyme Partners with Incyte on Enhanze Subcutaneous Formulation for Inca033989 Antibody

Reuters
·
Jul 20

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of Inca033989 Using Its Enhanze® Technology

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Eligible to Receive Royalties on Net Sales of Enhanze Medicines

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - to Receive Upfront Payment and Eligible for Milestone Payments from Incyte

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Incyte Granted Rights to Develop Enhanze with Mutcalr Program and Option for Two Additional Targets

THOMSON REUTERS
·
Jul 20

Incyte (INCY) Reports Promising Latarcibart Data As Global Phase 3 Begins

Simply Wall St.
·
Jul 17

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Incyte CMO Steven H. Stein Disposes of 53,155 Shares Worth $6.05 Million

Reuters
·
Jul 17

BofA Securities Raises Incyte Price Target to $136 From $124

MT Newswires Live
·
Jul 15

Incyte price target raised to $136 from $124 at BofA

TIPRANKS
·
Jul 15

Incyte : Bofa Global Research Raises Price Objective to $136 from $124

THOMSON REUTERS
·
Jul 15

Incyte: Early Strength in VGA039 Offsets Execution Risks; Salveen Richter Reiterates Hold and $100 Price Target

TIPRANKS
·
Jul 14

Incyte is Maintained at Overweight by Barclays

Dow Jones
·
Jul 14

Incyte: VGA039 Data Reinforces Diversification Strategy as Analyst Reiterates Hold and Keeps $103 Price Target Unchanged

TIPRANKS
·
Jul 14